Cargando…

Financial toxicity in patients with gynecologic malignancies: a cross sectional study

OBJECTIVE: To evaluate financial toxicity and assess its risk factors among patients with gynecologic cancers. METHODS: This is a cross sectional study that included 2 survey tools, as well as patient demographics, disease characteristics, and treatment regimen. Financial toxicity is measured by val...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeybek, Burak, Webster, Emily, Pogosian, Natalia, Tymon-Rosario, Joan, Balch, Alan, Altwerger, Gary, Clark, Mitchell, Menderes, Gulden, Huang, Gloria, Azodi, Masoud, Ratner, Elena S., Schwartz, Peter E., Santin, Alessandro D., Andikyan, Vaagn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550931/ https://www.ncbi.nlm.nih.gov/pubmed/34431257 http://dx.doi.org/10.3802/jgo.2021.32.e87

Ejemplares similares

Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study
por: Webster, Emily M., et al.
Publicado: (2020)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
por: Zeybek, Burak, et al.
Publicado: (2020)

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
por: Perrone, Emanuele, et al.
Publicado: (2020)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
por: Perrone, Emanuele, et al.
Publicado: (2020)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

Robot-Assisted Abdominal Cerclage During Pregnancy
por: Zeybek, Burak, et al.
Publicado: (2016)

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
por: Webster, Emily M., et al.
Publicado: (2020)

Port-Site Metastasis in Gynecological Malignancies
por: Benabou, Kelly, et al.
Publicado: (2021)

Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites
por: Li, Jessie Y., et al.
Publicado: (2021)

Opsoclonus-ataxia syndrome and mature ovarian teratoma in an adolescent
por: Webster, Emily M., et al.
Publicado: (2020)

Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature
por: Gressel, Gregory M., et al.
Publicado: (2015)

A Novel Approach to Combined Vaginal and Laparoscopic Gynecological Surgery
por: Tierney, Christina, et al.
Publicado: (2019)

Robotic radical trachelectomy with an abdominally placed vaginal cerclage for containment of early stage cervical cancer()
por: Tymon-Rosario, Joan, et al.
Publicado: (2020)

Robotic interval debulking with radical hysterectomy and partial urinary bladder resection for locally advanced carcinosarcoma of the uterus
por: Harold, Justin, et al.
Publicado: (2022)

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer
por: Albright, Benjamin B., et al.
Publicado: (2018)

An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva
por: Li, Jessie Y., et al.
Publicado: (2021)

Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer
por: Seifi, Farinaz, et al.
Publicado: (2019)

Transvaginal Morcellation
por: Clark Donat, Lindsay, et al.
Publicado: (2015)

Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities
por: AlAshqar, Abdelrahman, et al.
Publicado: (2023)

A Simple Approach to Specimen Retrieval via Posterior Colpotomy Incision
por: Clark, Lindsay E., et al.
Publicado: (2015)

WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type
por: Andikyan, Vaagn, et al.
Publicado: (2009)

Robotic Versus Abdominal Hysterectomy for Very Large Uteri
por: Silasi, Dan-Arin, et al.
Publicado: (2013)

Delayed presentation of placenta accreta following a first‐trimester medical abortion
por: Maurer, Jenna, et al.
Publicado: (2023)

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro
por: Ferrari, Francesca, et al.
Publicado: (2015)

Isolated torsion of the utero‐ovarian ligament
por: Hla, Audrey, et al.
Publicado: (2023)

Incisional infiltration versus transversus abdominis plane block of liposomal bupivacaine after midline vertical laparotomy for suspected gynecologic malignancy: a pilot study
por: Moon, Ashley S., et al.
Publicado: (2023)

Squamous cell carcinoma of the vulva arising in the setting of chronic hidradenitis suppurativa: A case report
por: Rekawek, Patricia, et al.
Publicado: (2016)

A case report of vulvar carcinoma in situ treated with sinecatechins with complete response()
por: Gupta, Natasha, et al.
Publicado: (2013)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo
por: Cocco, Emiliano, et al.
Publicado: (2016)

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma
por: Zeybek, Burak, et al.
Publicado: (2018)

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
por: Tymon-Rosario, Joan, et al.
Publicado: (2021)

Removal of 132-pound ovarian mucinous cystadenoma: A case report
por: Moon, Ashley S., et al.
Publicado: (2020)

Effectiveness of telehealth physical therapy for patients with pelvic floor disorders in a community hospital setting
por: Coad, Brady, et al.
Publicado: (2023)

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma
por: Damast, Shari, et al.
Publicado: (2015)

Selective Reduction of a Heterotopic Cesarean Scar Pregnancy Complicated by Septic Abortion
por: Tymon-Rosario, Joan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_npuh0r0ngnpbp3edsubuf3llif